|
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. |
|
|
Honoraria - Amgen; BMS GmbH & Co. KG; Celgene/Bristol-Myers Squibb; Molecular Partners; Novartis; Sanofi Aventis GmbH |
Consulting or Advisory Role - Amgen; BMS GmbH & Co. KG; Oncopeptides; Sanofi/Aventis |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst) |
Travel, Accommodations, Expenses - Amgen |
|
|
Honoraria - Janssen; Miltenyi Biotec; Sanofi |
Research Funding - Miltenyi Biotec |
Travel, Accommodations, Expenses - Janssen; Sanofi |
|
|
Travel, Accommodations, Expenses - Biotest; Takeda |
|
|
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda |
Research Funding - Abbvie; Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Janssen |
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen |
Travel, Accommodations, Expenses - Janssen |
|
|
Honoraria - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Biotech; Roche; Sanofi; Takeda |
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Roche; Sanofi; Takeda |
|
Marie von Lilienfeld-Toal |
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Chugai Pharma; Gilead Sciences; Janssen-Cilag; Medac; Merck KGaA; Novartis; Takeda |
Consulting or Advisory Role - 4D Pharma; Celgene; Gilead Sciences; Janssen; MSD; Oncopeptides; Shionogi |
Research Funding - Celgene; Gilead Sciences; Novartis; Oncopeptides |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; GlaxoSmithKline; Grifols; Takeda |
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Novartis; Sanofi; SOBI; Takeda |
Research Funding - Amgen; GlaxoSmithKline; Grifols; Janssen; Takeda |
|
|
Stock and Other Ownership Interests - Abbvie |
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Sanofi |
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Sanofi |
Research Funding - Bristol-Myers Squibb; Sanofi |
Travel, Accommodations, Expenses - Janssen |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Sanofi; Takeda |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Pfizer; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Kyowa Kirin; Pfizer; Takeda |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Kyowa Kirin; Pfizer; Takeda |
|
|
Honoraria - Amgen; Janssen-Cilag; Merck; MSD |
Consulting or Advisory Role - Janssen-Cilag; MSD |
Research Funding - Janssen-Cilag; Novartis |
|
|
Stock and Other Ownership Interests - Fate Therapeutics; Gilead Sciences; Ionis Pharmaceuticals; Nkarta |
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; BeiGene; Bristol-Myers Squibb; Janssen; Sanofi; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Janssen; Sanofi; Takeda |
Expert Testimony - Amgen; BeiGene; Bristol-Myers Squibb; Janssen; Sanofi; Takeda |
Travel, Accommodations, Expenses - Amgen; BeiGene; Bristol-Myers Squibb; Janssen; Sanofi; Takeda |
|
|
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Amgen; Becton Dickinson; Janssen; Jazz Pharmaceuticals; Pfizer |
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Novartis; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Novartis; Sanofi; Takeda |
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Celgene (Inst); GlaxoSmithKline; GlaxoSmithKline; Janssen (Inst); Sanofi |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Sanofi; Takeda |